Mabion S.A. (MAB) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Mabion S.A. PLN 2.02, price PLN 7.78, upside -74.0%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Mabion S.A. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 6.82 PLN – 84.30 PLN · fair‑value band 1.51 PLN – 3.01 PLN · the 7.78 PLN price screens above the 2.02 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Mabion in your weekly email
Every Wednesday you see whether Mabion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services.
Show more
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development, process development, production of a product for preclinical and clinical trials, development and validation of analytical methods, and preparation of the necessary documentation. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.
Stock analysis
Mabion S.A. (MAB) currently trades at 7.78 PLN, while our model-based Fair Value estimate is 2.02 PLN, implying the stock looks roughly 285.2% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 1.51 PLN (bear) to 3.01 PLN (bull), the price of 7.78 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Mabion S.A. reported revenue of 15.8M PLN in FY2025 versus 56.9M PLN in FY2021, a compound −27.4%/yr. Reported net income was −62.6M PLN in FY2025.
Key figures
Market cap 126M PLN (≈ $32.7M) · P/S ratio 6.70 · EPS (TTM) −3.53 PLN · Return on equity −84.3% · Return on assets (EBIT) −2.9% · Operating margin −201% · Revenue (TTM) 17.6M PLN · Revenue growth (YoY) +68.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −74%, MAB screens richer than that median.
Fair Value models
Bear 1.51 PLNFair Value 2.02 PLNBull 3.01 PLN
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.28/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−77.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−54.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.2%
Start year 2020 (pandemic). Over 10 years: +19.1% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.8%
’10
’11
’12
’14
’15
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,545.5% (2020) → −319.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−74% · Bottom 25%
Profitability
Return on assets−23% · Below median
Growth and dividend
Revenue growth68% · Top 25%
Balance sheet
Debt / equity0.21× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.67× · Cheaper than median
P/S (TTM)1.87× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)90· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Mabion S.A. Fair Value". https://www.fairvalue-calculator.com/stock/MAB
Frequently asked questions
Is Mabion S.A. (MAB) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2.02 PLN versus a price of 7.78 PLN, about −74% upside (overvalued).
What is the fair value of MAB?
Our model-based fair value for Mabion S.A. is 2.02 PLN (as of Sep 24, 2026), built from audited fundamentals. The current price: 7.78 PLN.
What is the quality score of MAB?
Mabion S.A. has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mabion S.A. (MAB)?
Our model-based price target is the fair value of 2.02 PLN (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 1.51 PLN, optimistic scenario 3.01 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Mabion S.A. stock forecast for 2026?
Our models put fair value at 2.02 PLN, about −74% upside versus a price of 7.78 PLN (overvalued). Cautious scenario 1.51 PLN, optimistic scenario 3.01 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Mabion S.A. (MAB)?
Mabion S.A. reported trailing-twelve-month revenue of about 17.6M PLN (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Mabion S.A. (MAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mabion S.A. it is 2.02 PLN per share (as of Sep 24, 2026), against a price of 7.78 PLN. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Mabion S.A. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MAB trades above its calculated fair value: price 7.78 PLN, fair value 2.02 PLN, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MAB?
No. The price is what the market pays today (7.78 PLN); the fair value is what the company's own numbers justify (2.02 PLN). For Mabion S.A. the two are 5.76 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Mabion S.A. worth?
The market values Mabion S.A. at about 126M PLN (market capitalisation, as of Sep 24, 2026). Per share that is 7.78 PLN; our models calculate a fair value of 2.02 PLN per share.
What do the bullish and bearish scenarios say about MAB?
Our models span a range for Mabion S.A.: cautious scenario 1.51 PLN, base 2.02 PLN, optimistic 3.01 PLN per share (as of Sep 24, 2026, price 7.78 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mabion S.A. (MAB)?
Balance-sheet figures for Mabion S.A. (as of Sep 24, 2026): return on equity −84.3%, debt of 0.21 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is MAB from its 52-week high?
Mabion S.A. trades at 7.78 PLN, about 19% below its 52-week high of 9.63 PLN and 14% above the low of 6.82 PLN (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 2.02 PLN is for.
Which stocks are comparable to Mabion S.A.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mabion S.A. stock attractive at the current price?
The data as of Sep 24, 2026: price 7.78 PLN, calculated fair value 2.02 PLN (−74%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MAB calculated?
We run Mabion S.A. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.02 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Mabion S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mabion S.A. (MAB)?
The closing price on Sep 24, 2026 was 7.78 PLN. Our model-based fair value is 2.02 PLN, about −74% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mabion S.A. right now?
The price sits above even our optimistic bull case (3.01 PLN). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1.51 PLN to 3.01 PLN) leaves room in how you read the outcome.
Key figures of Mabion S.A.
How large is the market capitalisation of Mabion S.A. (MAB)?
The market capitalisation of Mabion S.A. is 126M PLN (≈ $32.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mabion S.A. (MAB)?
The price-to-sales ratio of Mabion S.A. is 6.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mabion S.A. (MAB)?
Earnings per share at Mabion S.A. are −3.53 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Mabion S.A. (MAB)?
The return on equity (ROE) of Mabion S.A. is −84.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mabion S.A. (MAB)?
On an EBIT basis the return on assets of Mabion S.A. is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mabion S.A. (MAB)?
The operating margin of Mabion S.A. is −201% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mabion S.A. (MAB)?
Revenue at Mabion S.A. is growing +68.3% versus a year earlier (3y avg −54.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Mabion S.A. (MAB)?
Earnings per share at Mabion S.A. are growing −31.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Mabion S.A. (MAB) generate?
The free cash flow of Mabion S.A. is −42.5M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Mabion S.A. (MAB) carry?
The net debt of Mabion S.A. is 4.0M PLN (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Mabion S.A. in the live analysis
One click puts Mabion S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
